NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Jasper Therapeutics, Inc. (JSPR) Stock Analysis

Jasper Therapeutics, Inc. (JSPR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

JSPR

$0.71

+$0.02 (+3.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JSPR with… →

JSPR Key Statistics

As of Sep 4, 2026
Trading
Open
$0.67
Previous Close
$0.69
Day's Range
0.66–0.71
52-Week Range
0.32–2.78
Volume
432.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.04
Valuation
Market Cap
$23.58M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.97
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$75.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.27M
1-Year Return
−73.64%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
1.45M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JSPR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−61.26%
2025−91.44%
2024+170.98%
2023+63.35%
2022−93.85%
2021−21.58%
2020+1.93%

As of September 4, 2026.

JSPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$75.80M—
2024$0.00−$71.27M—
2023$0.00−$64.47M—
2022$0.00−$37.69M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$83.88M−$75.80M—
2024$0.00—−$76.24M−$71.27M—
2023$0.00—−$68.86M−$64.47M—
2022$0.00—−$51.20M−$37.69M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JSPR Valuation vs Biotechnology Median

Median of 656 stocks
MetricJSPRBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Jasper Therapeutics, Inc. (JSPR) at $23.58M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 22 employees.

The 52-week range on file runs from $0.32 to $2.78. The most recent close on file for JSPR is $0.71, dated September 4, 2026. That is +$0.02 (+3.35%) against the previous close. The latest close sits 125.08% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $75.80M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.97.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 3.04. Daily returns over the trailing 6 years annualize to a volatility of 216.59%. Over the trailing twelve months the price has returned −73.64%. Measured over 5 years, that is −62.83% a year compounded.

Growth & Income

No dividend is on file for JSPR.

Across the complete calendar years on file, 2024 returned +170.98% and 2022 returned −93.85%. Of the 6 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −61.26% year to date.

Peer Comparison

Jasper Therapeutics, Inc. (JSPR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jasper Therapeutics, Inc. JSPR $23.58M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Jasper Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.

Visit website →